RxDoctor Payments Data

Becky Wells, PA

Medical · Meridian, IDNPI 1780617811

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations.

$1,413in general payments, 2019–2025

Across 67 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$239
  • Pfizer$156
  • AstraZeneca$122
  • Novo Nordisk$110
  • Lilly USA, LLC$107
  • Amgen$105
  • plus $573 from 13 others

What the payments were for

  • Food & beverage$1,413100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,413 in reported general payments places this provider in the 75th percentile of 265 medical providers in Idaho.

See all medical providers in Idaho

Medicare billing

Part B allowed, 2024
$19,304
Medicare patients
70
Services billed
295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide19$23,051
OzempicSemaglutide17$18,613
Pregabalin16$441
Losartan Potassium53$416
Levothyroxine Sodium55$399
Atorvastatin Calcium59$271
Omeprazole24$254
Potassium Chloride12$178
Metformin Hcl ErMetformin Hcl18$173
Gabapentin12$137
Metoprolol Succinate15$129
Zolpidem Tartrate11$128
Amlodipine Besylate37$122
Montelukast Sodium11$119
Rosuvastatin Calcium17$94

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$107$23,05119 claims
Novo NordiskOzempic$110$18,61317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 265 medical providers in Idaho.

Other medical in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →